Le Bozec Antoine, Guédon Marie, Brugel Mathias, Laurent Maeliss, Carlier Claire, Hettler Dominique, Perrier Marine, Aubert Léa, Slimano Florian, Mongaret Céline, Bouché Olivier
CHU Reims, Oncology Day-Hospital, Reims, France.
CHU Reims, Department of Pharmacy, Reims, France.
J Oncol Pharm Pract. 2023 Jul 12:10781552231187136. doi: 10.1177/10781552231187136.
The growing interest of cannabidiol (CBD) in medical care prompted French health authorities to explore the potential of CBD in cancer-related severe symptoms. This study aimed to assess the prevalence of CBD use among cancer patients with potential associated factors and to measure the cancer patient's health literacy (HL) on CBD consumption.
In a prospective study in oncology day-care hospital including patients from 29 October to 20 December 2021, we collected demographic, biological, and oncological characteristics. Patient CBD HL was measured by the hetero-questionnaire 8-item-CBD HL scale (HLS-8-CBD) whose conception has been validated by a psychometric analysis.
Among 363 participants, 20 patients (5.5%) reported CBD use. Factors associated with CBD use were: age <60 years (odd ratio = 7.80[1.36-13.32], < 10 versus ≥60 years), smoking history (OR = 5.53[1.81-16.88], < 0.01), and no smoking cessation (OR = 5.07[1.66-15.46], < 0.01). CBD use was also associated with a better CBD total HL score than non-users (-value = 0.02).
Identification of factors associated with CBD use and a relatively high patient CBD HL in CBD users showed that CBD use in cancer patients care represented a new concern and should enhance health professionals to consider CBD with its associated drug-related problems.
大麻二酚（CBD）在医疗保健领域的关注度不断提高，促使法国卫生当局探索其在癌症相关严重症状方面的潜力。本研究旨在评估癌症患者中CBD的使用 prevalence 及其潜在相关因素，并衡量癌症患者对CBD消费的健康素养（HL）。
在一家肿瘤日间护理医院进行的前瞻性研究中，纳入了2021年10月29日至12月20日的患者，我们收集了人口统计学、生物学和肿瘤学特征。通过8项CBD健康素养量表（HLS-8-CBD）对患者的CBD HL进行测量，该量表的构想已通过心理测量分析验证。
在363名参与者中，20名患者（5.5%）报告使用过CBD。与CBD使用相关的因素有：年龄<60岁（比值比=7.80[1.36-13.32]，<10岁与≥60岁相比）、吸烟史（OR=5.53[1.81-16.88]，<0.01）以及未戒烟（OR=5.07[1.66-15.46]，<0.01）。CBD使用者的CBD总HL得分也高于非使用者（-值=0.02）。
确定与CBD使用相关的因素以及CBD使用者中相对较高的患者CBD HL表明，在癌症患者护理中使用CBD是一个新的关注点，应促使卫生专业人员考虑CBD及其相关的药物相关问题。
